TrialBlood neoplasia2025

Improved survival with daratumumab-CyBorD compared with CyBorD as frontline therapy for AL amyloidosis.

Binoy Yohannan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.